SCHEMBL2659189

SCHEMBL2659189

CCCCNc1ccc2c(c1)C(=O)NC2=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 3/20 0.61
HPGD P15428 3/20 0.61
ALOX12 P18054 1/20 0.61
CHEK1 O14757 1/20 0.54
KMT2A Q03164 6/20 0.52
MEN1 O00255 4/20 0.52
CASP3 P42574 3/20 0.48
GLA P06280 1/20 0.48
AR P10275 1/20 0.46
CRBN Q96SW2 1/20 0.46
PPOX P50336 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GSK3B P49841 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
CTDSP1 Q9GZU7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22078662 0.84 KDM4E (0.48) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL6341593 0.83 KDM4E (0.58) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL6340923 0.81 KDM4E (0.49) KDM4EALDH1A1HPGDALOX12KMT2A
SCHEMBL24237000 0.81 ALDH1A1 (0.50) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL17145936 0.81 GSK3B (0.45) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL27371589 0.81 AR (0.46) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL9623183 0.79 KDM4E (0.48) KDM4EALDH1A1HPGDALOX12KMT2A
SCHEMBL8648644 0.79 CHEK1 (0.56) KDM4EALDH1A1HPGDALOX12CHEK1
SCHEMBL18984689 0.77 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1CASP3SMN1; SMN2
SCHEMBL28111786 0.77 KDM4E (0.41) KDM4EALDH1A1HPGDALOX12CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
CN-1356977-A Glucagon antagonists/inverse agonists NOVO NORDISK AS (DK) 2002-07-03 CN disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR KDM4E 3664/4885ALDH1A1 3968/4885HPGD 1678/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR KDM4E 3664/4885ALDH1A1 3968/4885HPGD 1678/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR KDM4E 3664/4885ALDH1A1 3968/4885HPGD 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.